Stay updated on Pembrolizumab Ipilimumab Melanoma Immunotherapy Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Ipilimumab Melanoma Immunotherapy Clinical Trial page.

Latest updates to the Pembrolizumab Ipilimumab Melanoma Immunotherapy Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedMelanoma and related topics MedlinePlus Genetics were added, and the revision label was updated from v3.4.1 to v3.4.2.SummaryDifference0.2%

- Check20 days agoChange DetectedRevision added: v3.4.1. Melanoma and MedlinePlus Genetics were removed from related topics, along with the Revision: v3.4.0 entry.SummaryDifference0.2%

- Check27 days agoChange DetectedAdded a glossary and related topic links (Melanoma and MedlinePlus Genetics) and updated revision metadata (Last Update Submitted that Met QC Criteria and Revision: v3.4.0). Removed older QC labels (Last Update Submitted that met QC Criteria, No FEAR Act data) and the prior revision version (v3.3.4).SummaryDifference0.4%

- Check42 days agoChange DetectedAdded Revision: v3.3.4 in the footer. Removed Melanoma and the related topic MedlinePlus Genetics, and removed Revision: v3.3.3 from the related topics.SummaryDifference0.2%

- Check49 days agoChange DetectedAdded related topics Melanoma and MedlinePlus Genetics to the page.SummaryDifference0.2%

- Check63 days agoChange DetectedAdded a Locations section with state listings (Alabama, Florida, Illinois, Indiana, Virginia). Updated the page revision to v3.3.3.SummaryDifference0.8%

Stay in the know with updates to Pembrolizumab Ipilimumab Melanoma Immunotherapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Ipilimumab Melanoma Immunotherapy Clinical Trial page.